{
    "clinical_study": {
        "@rank": "60254", 
        "acronym": "CHEMO-T", 
        "arm_group": [
            {
                "arm_group_label": "Chemotherapy GEM-P", 
                "arm_group_type": "Experimental", 
                "description": "Gemcitabine, Methylprednisolone, Cisplatin"
            }, 
            {
                "arm_group_label": "Chemotherapy CHOP", 
                "arm_group_type": "Active Comparator", 
                "description": "Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised, open-label phase II study comparing GEM-P chemotherapy (experimental\n      arm) with CHOP (control arm) in previously untreated T-cell lymphoma. Eligible patients will\n      be randomised 1:1 between 4-weekly GEM-P or 3-weekly CHOP chemotherapy."
        }, 
        "brief_title": "CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study", 
        "completion_date": {
            "#text": "August 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral T-cell Lymphoma NOS", 
            "Anaplastic Large Cell Lymphoma, ALK-Negative", 
            "Angioimmunoblastic T-cell Lymphoma", 
            "Hepatosplenic Gamma/ Delta T-cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Immunoblastic Lymphadenopathy", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Peripheral", 
                "Lymphoma, Large-Cell, Anaplastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Background: T-cell lymphoma is an aggressive rare subset of Non-Hodgkin lymphoma (NHL)\n      comprising several different subtypes of disease within this group. No standard first-line\n      treatment exists for T-cell lymphoma as published series are small, with heterogeneous\n      populations and often retrospective.\n\n      PROTOCOL SYNOPSIS Study Period: 5 years\n\n      Objectives:\n\n      Primary\n\n      \u2022 To compare the complete response rate of GEM-P with CHOP chemotherapy in the first line\n      treatment of patients with T - cell Lymphoma. Secondary\n\n      To investigate, between both arms:\n\n        -  Rate of metabolic complete response\n\n        -  Toxicity of treatment\n\n        -  Overall survival (OS)\n\n        -  Progression Free Survival (PFS) Exploratory\n\n        -  Investigate impact of International Prognostic Index(IPI) on the outcomes response\n           rate, PFS and OS Study Design: A randomised multi-centre open-label phase II study\n           Indication: Previously untreated T-Cell lymphoma No of Participants: 186 (93 patients\n           in each arm) Main Eligibility Criteria\n\n        -  Histologically proven T-cell lymphoma of the following subtypes:\n\n        -  Peripheral T-cell lymphoma NOS\n\n        -  Systemic Anaplastic large cell lymphoma (ALCL) Anaplastic lymphoma kinase (ALK)negative\n           cases only\n\n        -  Angioimmunoblastic T-cell lymphoma\n\n        -  Hepatosplenic gamma/ delta T-cell lymphoma\n\n        -  Bulky Stage I, Stage II, III or IV\n\n        -  No prior chemotherapy regimen\n\n        -  Patients aged 18 years or over.\n\n        -  WHO performance status 0,1 or 2\n\n        -  Adequate organ function:\n\n        -  No Central Nervous System(CNS) or leptomeningeal involvement with lymphoma\n\n        -  No treatment for lymphoma within 4 weeks of commencing trial therapy\n\n        -  No known HIV, Hepatitis C or active Hepatitis B viral infection\n\n      Treatment:\n\n      CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 days. GEM-P:\n      gemcitabine, methylprednisolone, cisplatin every 28 days.\n\n      Assessment Schedule:\n\n        -  Patients will be reviewed at baseline and prior to each scheduled dose of treatment for\n           toxicity\n\n        -  Radiological tumour assessment will be done with CT scan after every 2 cycles in Arm A\n           and after cycle 1, 3 and 4 in Arm B\n\n        -  PET/CT scan will be performed at baseline and upon completion of treatment..\n\n        -  Follow up after completion of treatment will be 3, 6, 9, 12, 18, 24 months then\n           annually for 5 years in total. CT scan will be performed at 3 & 12 months.\n\n        -  Following disease progression patients will be followed for survival every 3 months\n           until death"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously untreated, histologically proven T-cell Lymphoma (any of the following):\n\n               -  Peripheral T-cell lymphoma Not Otherwise Specified (PTCL NOS)\n\n               -  Systemic Anaplastic large cell lymphoma (ALCL) ALK negative cases only\n\n               -  Angioimmunoblastic T-cell lymphoma\n\n               -  Hepatosplenic gamma/ delta T-cell lymphoma\n\n          -  Bulky stage I not being considered for reduced chemotherapy plus involved field\n             radiotherapy or stage II, III or IV.\n\n          -  Patient is male or female, and \u226518 years of age on the day of signing informed\n             consent.\n\n          -  WHO performance status 0, 1 or 2.\n\n          -  Cross sectional imaging from a baseline contrast enhanced CT should show at least one\n             measurable disease site that is at least 2 cm in longest diameter and measurable in\n             two perpendicular dimensions with or without corresponding Fluorodeoxyglucose(FDG)\n             avid lesions.\n\n          -  Adequate cardiac function; formal assessment of left ventricular ejection fraction is\n             only required if clinically indicated (a baseline echocardiogram should be done for\n             patients with either hypertension, age > 60 years or history of cardiac disease)\n\n          -  Adequate bone marrow function: absolute neutrophil count (ANC) \u22651.0x109/l; white\n             blood cell count \u2265 3x109/l; platelets \u2265 100x109/l; haemoglobin (Hb) \u2265 9g/dl (can be\n             post-transfusion), unless deemed disease related\n\n          -  Adequate renal function: calculated creatinine clearance \u226550ml/minute.\n\n          -  Adequate liver function: serum bilirubin \u22641.5x Upper limit of normal (ULN); Alanine\n             transaminase/Aspartate transaminase (ALT/AST) \u22642.5x ULN; ALP \u22643x ULN (in the absence\n             of liver metastases). If liver metastases are present, ALT, AST or Alkaline\n             phosphatase (ALP) \u22645x ULN are permitted. Isolated hyperbilirubinaemia due to\n             Gilbert's disease is acceptable\n\n          -  Female patient of childbearing potential must have a negative serum or urine \u03b2-human\n             chorionic gonadotropin(hCG)pregnancy test at baseline.\n\n          -  Written informed consent must be obtained prior to start of study treatments. Scans\n             and bone marrow biopsies performed within 4 weeks of commencement of therapy will be\n             acceptable provided they have been performed according to study requirements.\n\n          -  Patient agreeable to use contraception for the period of study treatment and up to 12\n             months after the last dose of study drugs.\n\n        Exclusion Criteria:\n\n          -  Documented or symptomatic central nervous system involvement or leptomeningeal\n             disease.\n\n          -  Patients with no measurable disease on the contrast enhanced CT scan at baseline.\n\n          -  Any other clinically significant disease or co-morbidity which may adversely affect\n             the safe delivery of treatment within this trial.\n\n          -  Any other malignancies diagnosed or treated within the last 5 years (other than\n             curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the\n             cervix).\n\n          -  Treatment with another investigational agent within 30 days of commencing study\n             treatment.\n\n          -  Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C\n             virus, acute or active hepatitis B infection.\n\n          -  Patient is pregnant or breastfeeding, or expecting to conceive or father children\n             within one year of finishing study treatment.\n\n          -  Patients with poorly controlled diabetes mellitus\n\n          -  Hypersensitivity or contraindication to any of the study drugs as stated in the\n             Summaries of product characteristics(SmPCs)for each of the study drugs. Patients with\n             previous cardiac infarct but satisfactory cardiac function may be allowed at the\n             discretion of Chief Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "186", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719835", 
            "org_study_id": "RMH CCR: 3549", 
            "secondary_id": "2011-004146-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemotherapy CHOP", 
                "description": "750mg/m2 IV every 21 days", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemotherapy GEM-P", 
                "description": "1000mg/m2 IV Days 1, 8, 15 every 28 days", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemotherapy CHOP", 
                "description": "50mg/m2 IV every 21 days", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemotherapy CHOP", 
                "description": "1.4mg/m2 (max 2mg) IV every 21 days", 
                "intervention_name": "Vincristine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemotherapy CHOP", 
                "description": "40mg/m2 oral Days 1-5 every 21 days", 
                "intervention_name": "Prednisolone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemotherapy GEM-P", 
                "description": "1000mg oral or IV Days 1-5 every 28 days", 
                "intervention_name": "methylprednisolone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemotherapy GEM-P", 
                "description": "100mg/m2 IV Day 15 every 28 days", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Vincristine", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "T cell lymphoma", 
            "untreated"
        ], 
        "lastchanged_date": "October 30, 2012", 
        "location": {
            "contact": {
                "email": "yemong.to@rmh.nhs.uk", 
                "last_name": "Ye mong To, BSc (Hons)", 
                "phone": "+44 (0) 208 661 3807"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SM2 5PT"
                }, 
                "name": "Royal Marsden NHS Foundation Trust - London and Surrey"
            }, 
            "investigator": {
                "last_name": "David Cunningham, MD FRCP", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study", 
        "overall_contact": {
            "email": "david.cunningham@rmh.nhs.uk", 
            "last_name": "David Cunningham, MD FRCP", 
            "phone": "+44 (0) 208 661 3156"
        }, 
        "overall_official": {
            "affiliation": "Royal Marsden NHS Foundation Trust", 
            "last_name": "David Cunningham, MD FRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Health Service", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "complete response rate (CR/CRu)", 
            "safety_issue": "No", 
            "time_frame": "approximately 20 weeks after randomisation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719835"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "using Common Terminology Criteria for Adverse Events (CTCAE)v4.0", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 20 weeks after randomisation"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "Progression Free survival", 
                "safety_issue": "No", 
                "time_frame": "1 and 2 years"
            }, 
            {
                "measure": "Metabolic Complete Response Rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 20 weeks after randomisation"
            }
        ], 
        "source": "Royal Marsden NHS Foundation Trust", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Research UK", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}